|THRX -- USA Stock|| |
null 9.81 9.81 9,223,372,036,855%
Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Theravance is 'Not Rated'
. Macroaxis provides Theravance buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Theravance positions. The advice algorithm takes into account all of Theravance available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Theravance buy-and-hold prospective. Also please take a look at World Market Map
Theravance Current Recommendation
For the selected time horizon Theravance has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
We provide advice to complement the current expert consensus
on Theravance. Our dynamic recommendation engine harnesses multi - dimensional algorithm to analyze the corporation potential to grow using all technical and fundamental data available at the time. To make sure Theravance is not overpriced, please validate all Theravance fundamentals including its Cash per Share
, and the relationship
between Price to Book
and Number of Employees
. Given that Theravance
has Number of Shares Shorted
of 24.88 M, we advise you double-check Theravance market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.
|Theravance generates negative expected return over the last 30 days|
|Theravance has high likelihood to experience some financial distress in the next 2 years|
|The company reported previous year revenue of 38.39 M. Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 8.43 M. |
|THERAVANCE currently holds about 206.19 M in cash with (1.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.76. |
|Over 86.0% of the company shares are owned by institutional investors|
Fama and French focus on testing asset pricing under different economic assumptions. Business Services theme has 61 constituents.